ProMetic Life Sciences (TSE:PLI) Trading 0.2% Higher – Should You Buy?

ProMetic Life Sciences Inc. (TSE:PLIGet Free Report) traded up 0.2% during trading on Monday . The stock traded as high as C$13.72 and last traded at C$13.60. 921 shares were traded during trading, a decline of 88% from the average session volume of 8,002 shares. The stock had previously closed at C$13.57.

ProMetic Life Sciences Price Performance

The stock has a market capitalization of C$317.06 million and a P/E ratio of -0.22. The company has a debt-to-equity ratio of 37.47, a quick ratio of 3.66 and a current ratio of 4.06. The stock’s 50-day moving average is C$13.60.

ProMetic Life Sciences Company Profile

(Get Free Report)

Prometic Life Sciences Inc operates as a biopharmaceutical company with two drug discovery platforms that focuses on unmet medical needs in the field of fibrosis and orphan diseases. Its product pipeline includes PBI-4050, an orally active lead drug candidate for fibrosis; plasminogen, a biopharmaceutical for the treatment of congenital plasminogen deficiency; and intravenous immunoglobulin, a preparation of antibodies purified from plasma donations from healthy individuals.

See Also

Receive News & Ratings for ProMetic Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProMetic Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.